Antimicrobial Resistance and Stewardship in the Time of COVID-19 Pandemic
A special issue of Infectious Disease Reports (ISSN 2036-7449).
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 4460
Special Issue Editors
Interests: Clostridioides difficile infection; antimicrobial resistance; antimicrobial treatment; immune response; host-pathogen interaction; human gut microbiota; infection control
Special Issues, Collections and Topics in MDPI journals
Interests: severe infections; infective endocarditis; emerging infections; infections in transplanted patients
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since 31 December 2019, the world has been shaken by the most profound health crisis of the last several decades. The coronavirus disease 2019 (COVID-19) rapidly became a pandemic, testing the resilience of health systems worldwide. Especially in critical areas, healthcare facilities suddenly faced high numbers of hospitalizations, shortages of beds, and the need to protect healthcare workers from COVID-19. The novelty and rapid spread of COVID-19 combined with the lack of high-level evidence on COVID-19 management led to the adoption of heterogeneous approaches and, probably, less attention being paid to the prevention of other bacterial infections.
The first available recommendations on the management of COVID-19 patients considered the use of empirical antibiotic treatment, resulting in a large use of antimicrobials. Therefore, compliance with antibiotic stewardship programs has been challenged during the pandemic.
Currently, we do not yet have a clear picture of the impact of the COVID-19 pandemic on compliance with antibiotic stewardship programs and the prevalence of multidrug-resistant bacterial infection.
The focus of this Special Issue includes any aspects concerning antimicrobial stewardship, infection control, and multidrug-resistant bacterial infections during the COVID-19 pandemic.
A better definition of the effect of infection control on the incidence of multidrug-resistant bacterial infection will be essential to improving the management of COVID-19 patients.
Dr. Guido Granata
Dr. Nicola Petrosillo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Infectious Disease Reports is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multidrug-resistant bacterial infection
- antibiotic stewardship
- COVID-19
- infection control
- antibiotics
